Stephen Thomas and the Art of the Next Pass

Stephen Thomas remembers the pass. In a regulation high school basketball game, he sent the ball off the backboard for a teammate to dunk. It was sufficiently memorable to survive into his executive biography, where the usual sequence of degrees and previous employers gives way to a small sporting confession. His coach immediately took him out of the game. One suspects the coach's version would have made an excellent companion piece.

Thomas calls it the highlight of his sporting career. The story has the agreeable economy of a good joke: setup, flourish, bench. It also gives a little air to a résumé crowded with companies whose names have changed, companies that have been acquired, and roles that have moved from scientific leadership to the chief executive's office. The basketball belongs to him. The metaphor that follows belongs to the reader.

“Coach subbed me out immediately.”

Stephen Thomas, on his high school basketball flourish

For much of his professional life, Thomas has worked at the point where one organization hands work to another. He co-founded Ichorion Therapeutics, which Cerecor acquired. He led science at ValenzaBio before its acquisition by Acelyrin. He co-founded and ran Tenet Medicines before Eliem Therapeutics acquired it. He now leads Sera Medicines, an accelerator that helps form and finance separate companies, including Navigator Medicines.

That sequence makes for a different kind of founder story. There is no single company name stretched across an entire career. Instead, there are laboratories, transactions, new management teams and continuing board responsibilities. Following Thomas means following the work through several doors. The names above those doors matter, but they do not tell the whole story.

Before the boardroom, the chemistry

His academic route began at Rensselaer Polytechnic Institute, where he earned a bachelor's degree in chemistry. In May 2010, the Dinolfo research group's news recorded his graduation and his next destination: Columbia. It is a pleasingly modest entry for the beginning of a career that would later involve financing announcements with nine figures. A student graduates. Another laboratory awaits.

At Columbia, Thomas earned a master's degree in chemistry with a focus on organic synthesis and a doctorate encompassing organic synthesis and chemical biology. His training came with a National Science Foundation predoctoral fellowship and a Bristol-Myers Squibb graduate fellowship. He had also been an Amgen Scholar. Those distinctions place his early career firmly inside scientific research, years before chief executive became his job title.

The educational sequence matters because it gives some substance to an otherwise slippery description: scientist turned founder. In Thomas's case, chemistry was a degree, a graduate specialty and a basis for his early leadership positions. The progression into business did not erase that beginning. His subsequent roles repeatedly combined responsibility for research with responsibility for the organization carrying it.

He identifies Metuchen, New Jersey, as his hometown and Chelsea FC as his favorite sports team. Geography, chemistry and football make a compact introduction. The basketball anecdote adds a fourth item: a willingness to put an unflattering ending beside a moment of flair. Even an executive biography can accommodate a substitution.

An acquisition, and another job to do

By September 2018, Thomas was the co-founder and chief scientific officer of Ichorion. Cerecor's announcement of its acquisition also set out what would happen to two of Ichorion's leaders. Patrick Crutcher would become vice president of business development. Thomas would become vice president and head of discovery, with responsibility for early development and portfolio management.

The change was concrete. A founder of a smaller company would now help direct a broader research portfolio within its acquirer. The transaction carried people into the next organization as well as assets. For Thomas, the acquisition appears in his career as both an ending and a new employment date. He remained at Cerecor, later renamed Avalo Therapeutics, until February 2020.

He then became chief scientific officer at ValenzaBio, a position he held from February 2020 to January 2023. His responsibilities extended into corporate strategy and fundraising. The combination is significant: choosing and advancing research programs was accompanied by work on how the company would support them. The scientific title covered part of the job, while the financing and strategy work widened its scope.

Acelyrin acquired ValenzaBio in January 2023. By then, Thomas had worked through two acquisitions from scientific leadership positions. It would be easy to make the transactions the entire plot. The more useful detail is the work between them: building portfolios, managing early development, helping shape strategy and participating in fundraising. An acquisition announcement compresses years into a paragraph. The employment dates restore some of the time.

Seven months at Tenet, a continuing seat

November 2023 brought another role: chief executive officer and director of Tenet Medicines. Thomas was also a co-founder. In April 2024, Eliem announced an agreement to acquire the company, and the acquisition closed on June 27. His tenure as Tenet CEO ran from November 2023 to June 2024. The short interval is striking, though a corporate calendar records a tenure rather than measuring all the work behind it.

The agreement named Thomas as the representative of Tenet's equityholders. That is a specific piece of responsibility inside a transaction with many participants. He also joined Eliem's board in connection with the acquisition. Aoife Brennan became the combined company's president and chief executive officer. Thomas's connection continued through a board seat and a consulting arrangement.

Eliem completed a $120 million private placement alongside the acquisition. That number belongs to the financing of the company. It should be read at that scale, alongside the change in ownership and management. Thomas was one participant in an arrangement involving existing investors, new investors, a buyer, a company being acquired and leaders taking on different responsibilities.

Eliem subsequently became Climb Bio, where Thomas remains listed as a board member. The sequence is useful to anyone trying to follow his career through a stack of company names. Tenet leads to Eliem; Eliem leads to Climb. Thomas's title changes along the way, but the connection survives the transaction. Here again, the next chapter involves staying involved while somebody else runs the company.

Building the place that builds companies

Sera adds another level to this pattern. Thomas has served as its chief executive officer and a director since November 2023. Rather than treating each new venture as an isolated beginning, Sera assembles capabilities that can help launch several companies. Its team includes scientific, manufacturing, operating, financial and business development experience. The model gives company formation an organization of its own.

William Bonificio is Sera's chief business officer, Naveen Daryani its chief strategy officer and Tatyana Touzova its chief operating officer. RA Capital Management has been a primary investor since Sera's founding in 2023. These names help make the structure legible: the chief executive works alongside colleagues with distinct operating responsibilities and a financial backer involved in company creation.

Sera describes a process of incubating programs and then establishing and financing spinouts when they reach an appropriate stage. Tenet and Navigator are two examples. For Thomas, this means his job can sit one level above the individual startup, inside the organization that helps prepare its launch. His experience with acquisitions and scientific leadership provides context for that position without requiring a grand theory of his motivations.

The distinction between parent and spinout also keeps the titles straight. Thomas is Sera's CEO. At Navigator, he is a co-founder and director who previously served as CEO. Each description identifies a different responsibility. A company can acquire its own management team while retaining a connection to the people and organization that helped establish it.

Navigator gets its own captain

Navigator was founded in 2024 as a Sera subsidiary. In August that year, it announced a $100 million Series A financing co-led by RA Capital Management and Forbion. The launch also included a licensing agreement with IMBiologics, a South Korean company. Scientific assets, financing and a new corporate organization arrived in the same announcement, a visible example of the company-building work surrounding Thomas.

He served as Navigator's chief executive from August 2024 to February 2025. On February 11, 2025, Navigator announced Tausif “Tosh” Butt as CEO and Khurem Farooq as board chairman. Butt brought previous leadership experience at Idorsia and ChemoCentryx; Farooq had led Aiolos Bio and Gyroscope Therapeutics. Navigator was adding executives with their own histories of operating companies through changes in ownership.

Thomas remains on Navigator's board. That detail gives the story its present shape: he leads the accelerator and continues in governance at a company it helped launch. His professional identity spans the starting stage and the continuing obligation. The founder remains connected while another chief executive takes charge of daily leadership. The handoff has names, titles and a date. It is also a reminder that the founding team and the operating team need not remain identical throughout a company’s life. Navigator’s own leadership history shows those responsibilities moving between people while the board connection continues.

The high school pass is still the most compact story Thomas tells about himself. It has a teammate, an improbable route to the basket and an ending he can laugh about. His professional career requires a longer scorebook: chemistry degrees, research portfolios, acquisitions, financing rounds and board seats. Across that record, a recurring event is easy to see. A company changes hands or leadership, and Thomas takes up another responsibility. There is usually more work after the pass.